SHA: 600196

Explore the latest insights on SHA: 600196 and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of SHA: 600196’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Grünenthal to Acquire Bayer's Stivarga (Regorafenib) for Up to €375 Million – Oral Multikinase Oncology Franchise Changes Hands Ahead of 2029–2030 Loss of Exclusivity
Others

Grünenthal to Acquire Bayer’s Stivarga (Regorafenib) for Up to €375 Million – Oral Multikinase Oncology Franchise Changes Hands Ahead of 2029–2030 Loss of Exclusivity

Grünenthal GmbH announced an agreement with Bayer AG (ETR: BAYN) to acquire Stivarga (regorafenib) for up to €375 million, bringing the approved oral multikinase inhibitor – marketed in more than…

Shanghai Shenqi Medical Partners with Bio-heart to Commercialize BioHeart Bioresorbable Sirolimus‑Eluting Coronary Stent – Ultra‑Thin 90μm Strut Design Targets Deliverability and Radial Strength

Shanghai Shenqi Medical Partners with Bio-heart to Commercialize BioHeart Bioresorbable Sirolimus‑Eluting Coronary Stent – Ultra‑Thin 90μm Strut Design Targets Deliverability and Radial Strength

HanX Biopharmaceuticals Signs Long‑Term Strategic Cooperation and AI Platform License with XtalPi Science – AI for Science to Power Antibody Design and Innovative Molecule Discovery

HanX Biopharmaceuticals Signs Long‑Term Strategic Cooperation and AI Platform License with XtalPi Science – AI for Science to Power Antibody Design and Innovative Molecule Discovery

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Shanghai Fosun Pharma and Meiji Seika Pharma Launch Phase III Studies for Anti-Infective Nacubactam

Company

Shanghai Fosun Pharma Reports 2023 Revenues, Highlights Innovation and R&D Progress

CompanyMedical Device

Intuitive Surgical’s Ion Robotic System Gains Regulatory Approval in China

CompanyDeals

Fosun Pharma Launches RMB 5 Billion Fund to Boost Biopharmaceutical Investments in Shenzhen

CompanyDrug

Fosun Pharmaceutical Gets NMPA Green Light for Phase I Study of Fibrosis Drug HLX6018

CompanyDrug

Shanghai Fosun Pharma Gets NMPA Green Light for Universal NK Cell Therapy GCK-01 Clinical Study

CompanyDrug

Shanghai Fosun Pharma Gets NMPA Green Light for XS-02 Solid Tumor Clinical Study

CompanyDrug

Shanghai Fosun Pharma’s GCK-01 CAR-NK Cell Therapy Gets Tacit Clinical Approval from China’s CDE

Show More